PDF(Pubmed)
Abstract：
Breast cancer is the most common malignancy and ranks second among the causes of tumor-associated death in females. The recurrence and drug resistance of breast cancer are intractable due to the presence of breast cancer stem cells (BCSCs), which are adequate to initiate tumor formation and refractory to conventional remedies. Runt-related transcription factor 2 (RUNX2), a pivotal transcription factor in mammary gland and bone development, has also been related to metastatic cancer and BCSCs. State-of-the-art research has indicated the retention of RUNX2 expression in a more invasive subtype of breast cancer, and in particular, triple-negative breast cancer development and drug resistance are associated with estrogen receptor signaling pathways. The present review mainly focused on the latest updates on RUNX2 in BCSCs and their roles in breast cancer progression and drug resistance, providing insight that may aid the development of RUNX2-based diagnostics and treatments for breast cancer in clinical practice.
摘要：
乳腺癌是最常见的恶性肿瘤，在女性肿瘤相关死亡原因中排名第二。由于乳腺癌干细胞(BCSCs)的存在，乳腺癌的复发和耐药性是棘手的，足以引发肿瘤形成，并且对常规疗法难以治疗。Runt相关转录因子2(RUNX2),乳腺和骨骼发育的关键转录因子，还与转移性癌症和BCSC有关。最先进的研究表明，RUNX2表达在更具侵袭性的乳腺癌亚型中保留，特别是,三阴性乳腺癌的发生和耐药与雌激素受体信号通路有关。本文主要综述了RUNX2在BCSC中的最新进展及其在乳腺癌进展和耐药中的作用。提供可能有助于在临床实践中开发基于RUNX2的乳腺癌诊断和治疗方法的见解。
